Radiopharm Theranostics Limited (AU:RAD) has released an update.
Radiopharm Theranostics Limited has announced a successful A$70 million capital raise, with significant investment from leading radiopharmaceutical company, Lantheus Holdings. The funding, which includes contributions from international institutional investors, will support the advancement of Radiopharm’s clinical programs until the end of 2026. Additionally, the arrangement includes the sale of two preclinical assets to Lantheus for A$3 million, bolstering Radiopharm’s position in the evolving field of cancer diagnosis and treatment.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.
